Assistant professor | Zagazig University | Egypt
Dr. Israa A. Seliem is a Lecturer in Pharmaceutical Organic Chemistry at the Faculty of Pharmacy, Zagazig University, with expertise in drug design, medicinal chemistry, and computational modeling. She earned her Ph.D. and M.S. in Pharmaceutical Organic Chemistry from Zagazig University and completed a research fellowship at Augusta State University, USA. Her professional contributions include teaching and supervising graduate and undergraduate research in organic and medicinal chemistry, designing curricula, and collaborating with colleagues to advance research in drug discovery. Dr. Seliem’s research focuses on the design, eco-friendly synthesis, and computational evaluation of novel therapeutic scaffolds, with significant work on anticancer, anticholinesterase, α-glucosidase, and anti-MRSA agents. She has an extensive publication record in leading journals such as RSC Advances, ChemMedChem, European Journal of Medicinal Chemistry, Bioorganic Chemistry, and Chemical Biology & Drug Design, covering areas like molecular docking, ADMET profiling, DFT studies, and drug-target interactions against EGFR, VEGFR-2, β-tubulin, and cytokines. Her work has also contributed to the development of antiviral agents targeting SARS-CoV-2 and antimycobacterial compounds. Dr. Seliem holds certifications including TEPH, IELTS, TOEFL, ICDL, and training in quality assurance, clinical pharmacology, and pharmaceutical sales. She is an active member of the scientific community through peer-reviewed publications, collaborations, and participation in research dissemination activities. Her consistent scholarly output and commitment to advancing pharmaceutical sciences make her a strong candidate for recognition through research excellence awards. She has 151 citations from 136 documents across 10 publications, with an h-index of 6.
Profile: Scopus | ORCID
Featured Publications
1. Seliem I.A.*, Design, eco-friendly synthesis, and molecular docking studies of isatin hybrids as promising therapeutic agents (anticancer, anticholinesterase inhibitor, α-glucosidase inhibitor, and anti-MRSA). RSC Adv., 2025.
2. Seliem I.A.*, Synthesis, cytotoxic activity, molecular docking, molecular dynamics simulations, and ADMET studies of novel spiropyrazoline oxindoles based on domino Knoevenagel–Michael cyclization as potent non-toxic anticancer agents targeting β-tubulin and EGFR, with anti-MRSA activity. RSC Adv., 2025.
3. Lotfy E.M., Bokhtia R.M., Abdel Fattah H.A., Seliem I.A.*, Microwave-assisted one-pot green synthesis, ADMET profiling, DFT, and molecular docking of novel 3-cyano-2-pyridone derivatives as dual EGFR and cytokine (TNF-α, IL-6) inhibitors. Eur. J. Med. Chem., 2025.
4. Seliem I.A.*, DMF-DMA catalyzed synthesis, molecular docking, in-vitro, in-silico design, and binding free energy studies of novel thiohydantoin derivatives as antioxidant and antiproliferative agents targeting EGFR tyrosine kinase and aromatase cytochrome P450 enzyme. Bioorg. Chem., 2024.
5. Seliem I.A., Panda S.S., Girgis A.S., Tran Q.L., Said M.F., Bekheit M.S., Abdelnaser A., Nasr S., Fayad W., Soliman A.A.F. et al., Development of isatin-based Schiff bases targeting VEGFR-2 inhibition: Synthesis, characterization, antiproliferative properties, and QSAR studies. ChemMedChem, 2022.
